Collagen Solutions PLC Third Medical Research Scotland Ph.D. Studentship

TIDMCOS

Collagen Solutions PLC

13 January 2017

Collagen Solutions Plc

(the "Company" or the "Group")

Awarded third Medical Research Scotland Ph.D. Studentship

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices, research and in-vitro diagnostics, announces that it has been awarded a third Medical Research Scotland Ph.D. studentship, this time in partnership with Professor Elizabeth Tanner, of the School of Engineering, at the University of Glasgow.

The project, titled "Collagen Calcium Phosphate Composite Devices for Bone Augmentation", will investigate the application of collagen fibrils to provide a scaffold for "critical size defects" in bone, which do not heal spontaneously. To obtain healing, some form of scaffold or conduit for the bone repair process is essential and this project will aim to develop novel collagen-containing biomaterials to aid the healing process for these larger bone defects. The project is a four-year Ph.D. project expected to start in the next academic year.

Commenting on the award, Jamal Rushdy, CEO of Collagen Solutions said: "Our current pipeline includes a novel bone graft substitute product, addressing a segment of the $1.7 billion end-user bone graft market opportunity. This new research programme, funded in collaboration with Medical Research Scotland and Professor Tanner's group within the world-class research facilities at the University of Glasgow, will ensure we continue to innovate in this field. In the future we hope to develop next-generation bone graft substitute technologies, addressing more difficult to heal bone defects, thus ensuring continued scientific leadership in this significant segment of the orthobiologics market."

About Professor Elizabeth Tanner, OBE:

Currently Professor of Biomedical Materials at the University of Glasgow, Professor Tanner received an OBE for services to Biomedical Engineering in 2016 and an honorary doctorate within the Faculty of Medicine, Lund University where she is a visiting Professor.

Her research interests are in the development and use of bioactive materials for bone augmentation and replacement, developing composites of polymers filled with bioactive ceramics based on the mineral phase of bone. One such material developed by her team is HAPEX(TM), used in over half a million patients since 1988. She has published over 150 papers and book chapters and in 2020 she will be President of the 11th World Biomaterials Congress taking place in Glasgow.

About Collagen Solutions:

Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The capabilities of the Company include the provision of native, soluble and powdered collagen formulations, processed and semi-processed tissues such as pericardium, bone, and blood vessels, and expertise in the development and contract manufacture of collagen components for use as engineered tissue scaffolds and other medical devices. These products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology. Collagen Solutions' unique offering extends beyond material supply and contract services through the highly skilled staff who support customers through the various stages of development and regulatory approval. For additional information, please visit www.collagensolutions.com.

Enquiries:

 
  Collagen Solutions Plc                                            Contact via Walbrook 
 Jamal Rushdy, Chief Executive 
  Officer 
 Gill Black, Chief Financial 
  Officer 
 
 Cenkos Securities plc (Nominated                                     Tel: 0207 397 8900 
  Adviser and Broker) 
  Stephen Keys 
  Steve Cox 
 
 Walbrook PR                           Tel: 020 7933 8780 or collagen@walbrookpr.com 
 Mike Wort                                                            Mob: 07900 608 002 
 Anna Dunphy                                                          Mob: 07876 741 001

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAKLLFFDFFXBBQ

(END) Dow Jones Newswires

January 13, 2017 02:00 ET (07:00 GMT)

Healthcare Inv (LSE:HIO)
Historical Stock Chart
From Apr 2024 to May 2024